Pharmacia & Upjohn S.p.a.

Farmitalia Carlo Erba S.r.l.

Pfizer Italia S.r.l.

Nerviano Medical Sciences S.r.l.

Istituto Europeo Di Oncologia S.r.l.

Pharmacia Italia S.p.a.

University System of Maryland

Newron Pharmaceuticals S.p.a.

Dac S.r.l.

Other

Pharmacia S.p.a.

Pharmacia & Upjohn Company

Ifom Fondazione Istituto Firc Di Oncologia Molecolare

Ieo - Istituto Europeo Di Oncologia S.r.l.

Pharmacia & Tubjohn Spa

Mario Varasi

Paolo Pevarello

Daniele Fancelli

Manuela Villa

Paola Vianello

Carmela Speciale

Ciro Mercurio

Franco Heidempergher

Patricia Salvati

Alberto Bonsignori

Tiziano Bandiera

Paolo Orsini

Gabriella Traquandi

Sergio Mantegani

Raffaella Amici

Carla Caccia

Philippe L Dostert

Antonio Giordani

Alberto Bianchetti

Simona Bindi

Saverio Minucci

Maria Gabriella Brasca

Anna Vulpetti

Florian Thaler

Antonio Longo

Robert Schwarcz

Martha A Warpehoski

Piero Melloni

Marcella Nesi

Andrea Lombardi Borgia

Paolo Polucci

Barbara Salom

Jacqueline Lansen

Mauro Angiolini

Barbara Forte

Sergio Vioglio

Walter Cabri

Antonino Suarato

Michele Caruso

Angelo Bedeschi

Ermes Vanotti

Ilaria Candiani

Antonio Pillan

Stefania Gagliardi

Anna Cappa

Giacomo Carenzi

Valeria Pittala′

Luca Sartori

Arturo Della Torre

Romeo Roncucci

Nicola Carfagna

Alessia Romussi

Roberto Tonani

Edward L Fritzen

Betsy S Pierce

Claes Post

Agnese Abate

Giuseppe Meroni

Ruggero Fariello

Teresa Disingrini

Marco Ballarini

Maria A Cervini

Gilles Pain

Dania Tesei

Massimo Cini

Jürgen Moll

Valeria Pittalà

Valeria Pittal&agrave;

Paolo Trifiro′

Roberto Commisso

Claudio Arrigoni

Loris Moretti

Simon Plyte

Roberto D'Alessio

Enzo Brambilla

Marcello Marchi

Roberto Maj

Antonella Isacchi

Antonello Mai

Marcellino Tibolla

Silvia De Bernardinis

Claudia Piutti

Paolo Cremonesi

Alessia Montagnoli

Jurgen Moll

Simona Polo

Paolo Trifiro'

Andrea Colombo

Corrado Santocanale

Maria Grabriella Brasca

Elena Maspero

Maurizio Meroni

Sebastiano Pasqualato

Sergio Valente

Maria Carmela Fulco

Maurizio Pasi

Giovanni Faga'

Elisa Zagarri

The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation.

HECT E3 ligase inhibitors and uses thereof

The present application relates to compounds of formula (I), wherein A, R, R, and Rare as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. 

Indole derivatives as histone demethylase inhibitors

The present invention relates to imidazole derivatives, wherein A, R, R, and Rare as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. 

Imidazoles as histone demethylase inhibitors

The present invention relates to imidazole derivatives of Formula (I), wherein A, R, R, and Rare as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. 

The present disclosure relates to cyclopropyl compounds of general formula (I), wherein R, and Rare as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. 

Cyclopropylamine compounds as histone demethylase inhibitors

The present application relates to thienopyrrole derivatives, compounds of Formulas (I) and (Ia), wherein R, R, Rand Rare as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting KDM1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity. 

Thienopyrroles as histone demethylase inhibitors

The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R, and Rare as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. 

Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A

Compounds which are tricyclopyrazole derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Tricyclopyrazole derivatives

This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; Ris hydrogen; C-Calkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R; (SO)R; cycloalkyl; aryl; or heteroaryl; Ris C-Calkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R; X is CH, oxygen or NR; Y is a bond, CHRor NR; Z is oxygen, CRRor C&#x2550;R; and R, R, R, R, R, R, R, Rand Rare as further defined in the specification; and pharmaceutical acceptable salts thereof. 

Spirocyclic derivatives as histone deacetylase inhibitors

This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C-Calkyl, optionally substituted by C-Ccycloalkyl, C-Caryl or hetero(C-C)aryl; (CO)R; (SO)R; C-Ccycloalkyl; C-Caryl; or hetero(C-C)aryl; Ris halogen, C-Calkyl, C-Chaloalkyl, C-Calkoxy, C-Chaloalkoxy; Y is CHor NR; Z is C&#x2550;R; and R, R, R, and Rare as further defined in the specification; and pharmaceutical acceptable salts thereof. 

Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R', R&#x2033;, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them. 

Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition

Thieno[2,3-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors

Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition

Growing community of inventors

Milan, Italy

Mario Varasi